FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Daniel Salazar

Research Profile

Chemicals & Drugs

Physiology

Procedures

Concepts & Ideas

Disorders

Obesity

Living Beings

Co-author Network

Publications

TOP 3
David S Small; Nagy A Farid; Christopher D Payne; Christopher S Konkoy; Joseph A Jakubowski; Kenneth J Winters; Daniel Salazar
Effect of intrinsic and extrinsic factors on the clinical pharmacokinetics and pharmacodynamics of prasugrel.
David S Small; Prajakti Kothare; Eunice Yuen; D Richard Lachno; Ying G Li; Kenneth J Winters; Nagy A Farid; Lan Ni; Joseph A Jakubowski; Daniel Salazar; Vivian T Thieu; Christopher D Payne
The pharmacokinetics and pharmacodynamics of prasugrel in healthy Chinese, Japanese, and Korean subjects compared with healthy Caucasian subjects.
David S Small; R E Wrishko; C Steven Ernest; L Ni; Kenneth J Winters; Nagy A Farid; Y G Li; John T Brandt; Daniel Salazar; Anthony G Borel; K A Kles; Christopher D Payne
Prasugrel pharmacokinetics and pharmacodynamics in subjects with moderate renal impairment and end-stage renal disease.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Daniel Salazar (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2010: David S Small; Nagy A Farid; Christopher D Payne; Christopher S Konkoy; Joseph A Jakubowski; Kenneth J Winters; Daniel Salazar
Effect of intrinsic and extrinsic factors on the clinical pharmacokinetics and pharmacodynamics of prasugrel.
Clinical pharmacokinetics 2010;49(12):777-98.
2010: David S Small; Prajakti Kothare; Eunice Yuen; D Richard Lachno; Ying G Li; Kenneth J Winters; Nagy A Farid; Lan Ni; Joseph A Jakubowski; Daniel Salazar; Vivian T Thieu; Christopher D Payne
The pharmacokinetics and pharmacodynamics of prasugrel in healthy Chinese, Japanese, and Korean subjects compared with healthy Caucasian subjects.
European journal of clinical pharmacology 2010;66(2):127-35.
2009: David S Small; R E Wrishko; C Steven Ernest; L Ni; Kenneth J Winters; Nagy A Farid; Y G Li; John T Brandt; Daniel Salazar; Anthony G Borel; K A Kles; Christopher D Payne
Prasugrel pharmacokinetics and pharmacodynamics in subjects with moderate renal impairment and end-stage renal disease.
Journal of clinical pharmacy and therapeutics 2009;34(5):585-94.
2009: David S Small; Nagy A Farid; Y G Li; C Steven Ernest; Kenneth J Winters; Daniel Salazar; Christopher D Payne
Pharmacokinetics and pharmacodynamics of prasugrel in subjects with moderate liver disease.
Journal of clinical pharmacy and therapeutics 2009;34(5):575-83.
2009: Rebecca E Wrishko; C Steven Ernest; David S Small; Ying G Li; Govinda J Weerakkody; Jeffrey R Riesmeyer; William L Macias; Shashank Rohatagi; Daniel Salazar; Elliott M Antman; Stephen D Wiviott; Eugene Braunwald; Lan Ni
Population pharmacokinetic analyses to evaluate the influence of intrinsic and extrinsic factors on exposure of prasugrel active metabolite in TRITON-TIMI 38.
Journal of clinical pharmacology 2009;49(8):984-98.
2009: Nagy A Farid; Joseph A Jakubowski; Christopher D Payne; Y G Li; Y Jin; C S Ernest II; Kenneth J Winters; John T Brandt; Daniel Salazar; David S Small
Effect of rifampin on the pharmacokinetics and pharmacodynamics of prasugrel in healthy male subjects.
Current medical research and opinion 2009;25(8):1821-9.
2009: David S Small; Rebecca E Wrishko; C Steven Ernest; Lan Ni; Kenneth J Winters; Nagy A Farid; Ying G Li; Daniel Salazar; Christopher D Payne
Effect of age on the pharmacokinetics and pharmacodynamics of prasugrel during multiple dosing: an open-label, single-sequence, clinical trial.
Drugs & aging 2009;26(9):781-90.
2008: C Steven Ernest; David S Small; Shashank Rohatagi; Daniel Salazar; Lars Wallentin; Kenneth J Winters; Rebecca E Wrishko
Population pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel in aspirin-treated patients with stable coronary artery disease.
Journal of pharmacokinetics and pharmacodynamics 2008;35(6):593-618.
2008: David S Small; Nagy A Farid; Ying G Li; C Steven Ernest; Christopher D Payne; Daniel Salazar; Kenneth J Winters
Effect of ranitidine on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel.
Current medical research and opinion 2008;24(8):2251-7.
2008: David S Small; Nagy A Farid; Christopher D Payne; Govinda J Weerakkody; Ying G Li; John T Brandt; Daniel Salazar; Kenneth J Winters
Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel.
Journal of clinical pharmacology 2008;48(4):475-84.
2008: Joseph A Jakubowski; Christopher D Payne; Ying G Li; John T Brandt; David S Small; Nagy A Farid; Daniel Salazar; Kenneth J Winters
The use of the VerifyNow P2Y12 point-of-care device to monitor platelet function across a range of P2Y12 inhibition levels following prasugrel and clopidogrel administration.
Thrombosis and haemostasis 2008;99(2):409-15.
2008: Joseph A Jakubowski; Christopher D Payne; Ying G Li; Nagy A Farid; John T Brandt; David S Small; Daniel Salazar; Kenneth J Winters
A comparison of the antiplatelet effects of prasugrel and high-dose clopidogrel as assessed by VASP-phosphorylation and light transmission aggregometry.
Thrombosis and haemostasis 2008;99(1):215-22.
2008: Nagy A Farid; Christopher D Payne; C Steven Ernest; Y Grace Li; Kenneth J Winters; Daniel Salazar; David S Small
Prasugrel, a new thienopyridine antiplatelet drug, weakly inhibits cytochrome P450 2B6 in humans.
Journal of clinical pharmacology 2008;48(1):53-9.
2007: John T Brandt; S L Close; Stephen J Iturria; Christopher D Payne; Nagy A Farid; C Steven Ernest; D R Lachno; Daniel Salazar; Kenneth J Winters
Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel.
Journal of thrombosis and haemostasis : JTH 2007;5(12):2429-36.
2007: Christopher D Payne; Ying Grace Li; David S Small; C Steven Ernest; Nagy A Farid; Joseph A Jakubowski; John T Brandt; Daniel Salazar; Kenneth J Winters
Increased active metabolite formation explains the greater platelet inhibition with prasugrel compared to high-dose clopidogrel.
Journal of cardiovascular pharmacology 2007;50(5):555-62.
2007: Nagy A Farid; Christopher D Payne; David S Small; Kenneth J Winters; C Steven Ernest; John T Brandt; C Darstein; Joseph A Jakubowski; Daniel Salazar
Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently.
Clinical pharmacology and therapeutics 2007;81(5):735-41.
2007: S Rohatagi; H Kastrissios; Y Gao; N Zhang; J Xu; J Moberly; R Wada; K Yoshihara; M Takahashi; K Truitt; Daniel Salazar
Predictive population pharmacokinetic/pharmacodynamic model for a novel COX-2 inhibitor.
Journal of clinical pharmacology 2007;47(3):358-70.
2006: Randy C Dockens; Daniel Salazar; I Edgar Fulmor; Michele Wehling; Mark E Arnold; Robert Croop
Pharmacokinetics of a newly identified active metabolite of buspirone after administration of buspirone over its therapeutic dose range.
Journal of clinical pharmacology 2006;46(11):1308-12.
2006: H Kastrissios; S Rohatagi; J Moberly; K Truitt; Y Gao; R Wada; M Takahashi; K Kawabata; Daniel Salazar
Development of a predictive pharmacokinetic model for a novel cyclooxygenase-2 inhibitor.
Journal of clinical pharmacology 2006;46(5):537-48.
2006: Jean-Francois Marier; Rudolf Guilbaud; Siva Rama Prasad Kambhampati; Philip Mathew; James B Moberly; James Lee; Daniel Salazar
The effect of AST-120 on the single-dose pharmacokinetics of losartan and losartan acid (E-3174) in healthy subjects.
Journal of clinical pharmacology 2006;46(3):310-20.
2006: Jean-Francois Marier; James Lee; Siva Rama Prasad Kambhampati; Lawrence Galitz; Ramon Vargas; James B Moberly; Daniel Salazar
Effect of repeated oral administrations of the oral adsorbent AST-120 on serum creatinine and other markers of renal function. A randomized controlled study in patients with chronic kidney disease.
American journal of nephrology 2006;26(2):136-41.
2002: Edyta J Frackiewicz; Stanford S Jhee; Thomas Shiovitz; Jonathan Webster; Christine Topham; Randy C Dockens; Daisy B Whigan; Daniel Salazar; Neal R Cutler
Brasofensine treatment for Parkinson's disease in combination with levodopa/carbidopa.
The Annals of pharmacotherapy 2002;36(2):225-30.
2002: Dale O Kiesewetter; Elaine M Jagoda; John E Starrett; Valentin K Gribkoff; Piyasena Hewawasam; Nugahally Srinivas; Daniel Salazar; William Eckelman
Radiochemical synthesis and biodistribution of a novel maxi-K potassium channel opener.
Nuclear medicine and biology 2002;29(1):55-9.
2001: Daniel Salazar; Edyta J Frackiewicz; Randy C Dockens; GD Kollia; I Edgar Fulmor; P D Tigel; H D Uderman; Thomas Shiovitz; John J Sramek; Neal R Cutler
Pharmacokinetics and tolerability of buspirone during oral administration to children and adolescents with anxiety disorder and normal healthy adults.
Journal of clinical pharmacology 2001;41(12):1351-8.
2001: Darrell R. Abernethy; Jean T Barbey; J Franc; K S Brown; I Feirrera; N Ford; Daniel Salazar
Loratadine and terfenadine interaction with nefazodone: Both antihistamines are associated with QTc prolongation.
Clinical pharmacology and therapeutics 2001;69(3):96-103.
2000: C Laroudie; Daniel Salazar; J P Cosson; B Cheuvart; B Istin; J Girault; I Ingrand; JP Decourt
Carbamazepine-nefazodone interaction in healthy subjects.
Journal of clinical psychopharmacology 2000;20(1):46-53.
1999: Daniel Salazar; A J Fischman
Central nervous system pharmacokinetics of psychiatric drugs.
Journal of clinical pharmacology 1999;Suppl():10S-12S.
1999: A Sharma; William J Jusko; I Edgar Fulmor; J Norton; H D Uderman; Daniel Salazar
Pharmacokinetics and pharmacodynamics of avitriptan during intravenous administration in healthy subjects.
Journal of clinical pharmacology 1999;39(7):685-94.
1999: Stanford S Jhee; Daniel Salazar; N F Ford; I Edgar Fulmor; John J Sramek; Neal R Cutler
A double-blind, randomized, crossover assessment of blood pressure following administration of avitriptan, sumatriptan, or placebo to patients with mild to moderate hypertension.
Cephalalgia : an international journal of headache 1999;19(2):95-9.
1999: C Laroudie; Daniel Salazar; J P Cosson; B Cheuvart; B Istin; J Girault; I Ingrand; JP Decourt
Pharmacokinetic evaluation of co-administration of nefazodone and lithium in healthy subjects.
European journal of clinical pharmacology 1999;54(12):923-8.
1998: Neal R Cutler; Daniel Salazar; Stanford S Jhee; I Edgar Fulmor; N Ford; R A Smith; John J Sramek
Pharmacokinetics and pharmacodynamics of avitriptan in patients with migraine after oral dosing.
Headache 1998;38(6):446-52.
1998: Stanford S Jhee; Daniel Salazar; N F Ford; I Edgar Fulmor; John J Sramek; Neal R Cutler
Monitoring of acute migraine attacks: placebo response and safety data.
Headache 1998;38(1):35-8.
1997: Daniel Salazar; D R Much; PS Nichola; James R Seibold; D Shindler; P H Slugg
A pharmacokinetic-pharmacodynamic model of d-sotalol Q-Tc prolongation during intravenous administration to healthy subjects.
Journal of clinical pharmacology 1997;37(9):799-809.
1996: B T Christian; E Livni; John W Babich; Nathaniel M Alpert; D D Dischino; E Ruediger; Daniel Salazar; N F Ford; Alan J Fischman
Evaluation of cerebral pharmacokinetics of the novel antidepressant drug, BMS-181101, by positron emission tomography.
The Journal of pharmacology and experimental therapeutics 1996;279(1):325-31.
1995: DS Greene; Daniel Salazar; R C Dockens; Patricia D Kroboth; RH Barbhaiya
Coadministration of nefazodone and benzodiazepines: IV. A pharmacokinetic interaction study with lorazepam.
Journal of clinical psychopharmacology 1995;15(6):409-16.
1995: DS Greene; Daniel Salazar; R C Dockens; Patricia D Kroboth; RH Barbhaiya
Coadministration of nefazodone and benzodiazepines: III. A pharmacokinetic interaction study with alprazolam.
Journal of clinical psychopharmacology 1995;15(6):399-408.
1995: Daniel Salazar; Punit Marathe; I Edgar Fulmor; J S Lee; R H Raymond; Howard Uderman
Pharmacokinetic and pharmacodynamic evaluation during coadministration of nefazodone and propranolol in healthy men.
Journal of clinical pharmacology 1995;35(11):1109-18.
1995: Punit Marathe; Daniel Salazar; DS Greene; J Brennan; U A Shukla; RH Barbhaiya
Absorption and presystemic metabolism of nefazodone administered at different regions in the gastrointestinal tract of humans.
Pharmaceutical research 1995;12(11):1716-21.
1995: Patricia D Kroboth; M M Folan; R M Lush; P C Chaikin; U A Shukla; RH Barbhaiya; Daniel Salazar
Coadministration of nefazodone and benzodiazepines: I. Pharmacodynamic assessment.
Journal of clinical psychopharmacology 1995;15(5):306-19.
1995: Daniel Salazar; R C Dockens; R L Milbrath; R H Raymond; I Edgar Fulmor; P C Chaikin; Howard Uderman
Pharmacokinetic and pharmacodynamic evaluation of warfarin and nefazodone coadministration in healthy subjects.
Journal of clinical pharmacology 1995;35(7):730-8.
1994: Daniel Salazar; C L Sorge; S W Jordan; George B Corcoran
Obesity decreases hepatic glutathione concentrations and markedly potentiates allyl alcohol-induced periportal necrosis in the overfed rat.
International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity 1994;18(1):25-33.
1992: Daniel Salazar; J J Schentag; George B Corcoran
Obesity as a risk factor in drug-induced organ injury. V. Toxicokinetics of gentamicin in the obese overfed rat.
Drug metabolism and disposition: the biological fate of chemicals 1992;20(3):402-6.
1991: J A Wald; Daniel Salazar; H Y Chen; William J Jusko
Two-compartment basophil cell trafficking model for methylprednisolone pharmacodynamics.
Journal of pharmacokinetics and biopharmaceutics 1991;19(5):521-36.
1991: Judy L Raucy; Jerome M Lasker; J C Kraner; Daniel Salazar; C S Lieber; George B Corcoran
Induction of cytochrome P450IIE1 in the obese overfed rat.
Molecular pharmacology 1991;39(3):275-80.
1989: George B Corcoran; Daniel Salazar; H H Chan
Obesity as a risk factor in drug-induced organ injury. III. Increased liver and kidney injury by furosemide in the obese overfed rat.
Toxicology and applied pharmacology 1989;98(1):12-24.
1989: George B Corcoran; Daniel Salazar
Obesity as a risk factor in drug-induced organ injury. IV. Increased gentamicin nephrotoxicity in the obese overfed rat.
The Journal of pharmacology and experimental therapeutics 1989;248(1):17-22.
1989: George B Corcoran; Daniel Salazar; C L Sorge
Pharmacokinetic characteristics of the obese overfed rat.
International journal of obesity 1989;13(1):69-79.
1988: Daniel Salazar; C L Sorge; George B Corcoran
Obesity as a risk factor for drug-induced organ injury. VI. Increased hepatic P450 concentration and microsomal ethanol oxidizing activity in the obese overfed rat.
Biochemical and biophysical research communications 1988;157(1):315-20.
1988: George B Corcoran; Daniel Salazar
Obesity as a risk factor in drug induced organ injury. II. Increased renal cytochrome P-450 in the obese overfed rat.
Drug metabolism and disposition: the biological fate of chemicals 1988;16(6):898-900.
1988: George B Corcoran; Daniel Salazar; J J Schentag
Excessive aminoglycoside nephrotoxicity in obese patients.
The American journal of medicine 1988;85(2):279.
1988: Daniel Salazar; George B Corcoran
Predicting creatinine clearance and renal drug clearance in obese patients from estimated fat-free body mass.
The American journal of medicine 1988;84(6):1053-60.
1987: George B Corcoran; S J Chung; Daniel Salazar
Early inhibition of the Na+/K+-ATPase ion pump during acetaminophen-induced hepatotoxicity in rat.
Biochemical and biophysical research communications 1987;149(1):203-7.